Eryseng Parvo


Porcine parvovirus and Erysipelothrix rhusiopathiae

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 13/05/2019

Authorisation details

Product details
Eryseng Parvo
Agency product number
Active substance
porcine parvovirus, strain NADL-2 and Erysipelothrix rhusiopathiae, strain R32E11 (inactivated)
International non-proprietary name (INN) or common name
Porcine parvovirus and Erysipelothrix rhusiopathiae
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Laboratorios Hipra, S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Avda. La Selva, 135
17170 Amer

Product information

26/04/2019 Eryseng Parvo - EMEA/V/C/002762 - R/0006

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for suidae

  • Inactivated viral and inactivated bacterial vaccines

Therapeutic indication

For the active immunisation of female pigs for the protection of progeny against transplacental infection caused by porcine parvovirus.

For the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by Erysipelothrix rhusiopathiae, serotype 1 and serotype 2.

Assessment history

How useful was this page?

Add your rating